Drug major Pfizer has announced that its pneumococcal 20-valent conjugate vaccine Prevnar-20 was safe to be administered concurrently with its COVID19 vaccine and does not interfere with immune response in the patients’ bodies.
The announcement was made by the company on January 12, 2022, as a part of the results from a Phase 3 study (B7471026) describing the safety and immunogenicity of PREVNAR 20 in 570 adults in the United States 65 years of age or older when administered at the same time as the Pfizer-BioNTech COVID-19 Vaccine or when each vaccine was given with placebo.
“Pfizer is steadfast in its commitment to address the burden of certain respiratory diseases while raising awareness of the importance of adult immunisations,” said Kathrin U. Jansen, the Senior Vice President and Head of Vaccine Research & Development of Pfizer.
“These new safety and immunogenicity data provide further evidence supporting the potential to administer Prevnar 20 and the Pfizer-BioNTech COVID19 vaccine at the same time, thereby reducing the number of visits adults make to their doctor’s office or pharmacy for recommended immunisation,” she added.
The initiation of the study exploring the coadministration of Prevnar 20 along with a booster dose of the Pfizer-BioNTech COVID19 vaccine in older adults was announced in May 2021, a statement released by the company stated.
Pfizer informed that the study recruited adults from the pivotal Phase 3 Pfizer-BioNTech COVID19 vaccine clinical trial and included adults who received their second dose of the vaccine at least six months prior to entering the coadministration study.
“Pfizer will seek to present and publish detailed outcomes from this clinical trial at a future date; at this time no coadministration data are included in the Prevnar 20 or Pfizer-BioNTech COVID19 Vaccine prescribing information,” the statement added.
Prevnar 20 has been approved by the United States Food and Drug Administration (FDA) for the prevention of invasive disease and pneumonia caused by 20 Streptococcus pneumoniae (pneumococcus) serotypes in adults age 18 years or older, the company said.
Pivotal Phase 3 studies of the 20-valent pneumococcal conjugate vaccine candidate in infants are expected to read out in the second half of 2022 and, if positive, form the basis of potential regulatory submissions to the FDA and EMA later this year, the statement added.